SG11202111429UA - Use of an anti-cd19 antibody to treat autoimmune disease - Google Patents

Use of an anti-cd19 antibody to treat autoimmune disease

Info

Publication number
SG11202111429UA
SG11202111429UA SG11202111429UA SG11202111429UA SG11202111429UA SG 11202111429U A SG11202111429U A SG 11202111429UA SG 11202111429U A SG11202111429U A SG 11202111429UA SG 11202111429U A SG11202111429U A SG 11202111429UA SG 11202111429U A SG11202111429U A SG 11202111429UA
Authority
SG
Singapore
Prior art keywords
antibody
autoimmune disease
treat autoimmune
treat
disease
Prior art date
Application number
SG11202111429UA
Inventor
Eliezer Katz
Jorn Drappa
Kathleen Mckeever
Original Assignee
Viela Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viela Bio Inc filed Critical Viela Bio Inc
Publication of SG11202111429UA publication Critical patent/SG11202111429UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202111429UA 2019-04-24 2020-04-23 Use of an anti-cd19 antibody to treat autoimmune disease SG11202111429UA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962838093P 2019-04-24 2019-04-24
US201962843096P 2019-05-03 2019-05-03
US201962858495P 2019-06-07 2019-06-07
PCT/US2020/029613 WO2020219743A2 (en) 2019-04-24 2020-04-23 Use of an anti-cd19 antibody to treat autoimmune disease

Publications (1)

Publication Number Publication Date
SG11202111429UA true SG11202111429UA (en) 2021-11-29

Family

ID=72940915

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111429UA SG11202111429UA (en) 2019-04-24 2020-04-23 Use of an anti-cd19 antibody to treat autoimmune disease

Country Status (12)

Country Link
US (1) US20220204617A1 (en)
EP (1) EP3959241A4 (en)
JP (1) JP2022529743A (en)
KR (1) KR20220004113A (en)
CN (1) CN113939532A (en)
AU (1) AU2020263418A1 (en)
BR (1) BR112021020924A2 (en)
CA (1) CA3136487A1 (en)
IL (1) IL287385A (en)
MX (1) MX2021012870A (en)
SG (1) SG11202111429UA (en)
WO (1) WO2020219743A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3809260A1 (en) * 2019-10-18 2021-04-21 Siemens Healthcare GmbH System and method for monitoring production systems
IL308296A (en) * 2021-05-07 2024-01-01 Viela Bio Inc Use of an anti-cd19 antibody to treat myasthenia gravis
WO2024025602A1 (en) 2022-07-27 2024-02-01 Viela Bio, Inc. Inebilizumab and methods of using the same for sustained b-cell depletion

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009002414A (en) * 2006-09-08 2009-05-20 Medimmune Llc Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease.
EP2403532A4 (en) * 2009-03-06 2012-12-05 Medimmune Llc Humanized anti-cd19 antibody formulations
JP2015515456A (en) * 2012-03-12 2015-05-28 メディミューン，エルエルシー Treatment of multiple sclerosis with anti-CD19 antibody
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease

Also Published As

Publication number Publication date
AU2020263418A1 (en) 2021-11-11
JP2022529743A (en) 2022-06-23
BR112021020924A2 (en) 2022-04-19
WO2020219743A3 (en) 2020-12-10
KR20220004113A (en) 2022-01-11
CN113939532A (en) 2022-01-14
IL287385A (en) 2021-12-01
MX2021012870A (en) 2022-01-18
WO2020219743A2 (en) 2020-10-29
EP3959241A2 (en) 2022-03-02
EP3959241A4 (en) 2023-01-25
CA3136487A1 (en) 2020-10-29
US20220204617A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
IL277858A (en) Antibodies specific to human nectin4
IL287385A (en) Use of an anti-cd19 antibody to treat autoimmune disease
IL279053A (en) Anti-pvrig/anti-tigit bispecific antibodies and methods of use
CL2018000728A1 (en) Humanized human anti-cd19 antibodies and methods of use
HUE064454T2 (en) Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
IL277217A (en) Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
IL271266A (en) Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia
IL281449A (en) Anti-ifnar1 antibodies for treating autoimmune diseases
SG11202010367YA (en) Integration of high frequency reconstruction techniques with reduced post-processing delay
HK1249016A1 (en) Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
EP3716949A4 (en) Methods of treating autoimmune disease
ZA202104356B (en) Monoclonal antibodies that bind specifically to human trbv9
GB201804724D0 (en) Method of diagnosing cceliac disease
EP3523333C0 (en) Anti-ceacam6 antibodies and methods of use
EP3837286A4 (en) Antibodies to human znt8
IL284807A (en) Antibodies specific to human nectin-2
IL283136A (en) Antibodies to mucin-16 and methods of use thereof
MX2015015232A (en) Monoclonal antibody directed against cxcr5.
IL273538A (en) Anti-trkb monoclonal antibodies and methods of use
IL286099A (en) Methods of treating disease with levoketoconazole
IL269419A (en) Treatment of lupus using humanized anti-cxcr5 antibodies
EP3615561C0 (en) Variants of human bmp7 protein
GB201811375D0 (en) Treatment of autoimmune disease
GB201804603D0 (en) Treatment of antiretroviral disease
EP3883593A4 (en) Methods of treating an autoimmune disease